Valentina Trapani

Dr. Valentina Trapani

Patologia Generale, Facoltà di MEDICINA E CHIRURGIA, Università Cattolica del Sacro Cuore, Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2001 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IHIan Hutchinson
Ian Hutchinson
MCMei-Sze Chua
Mei-Sze Chua
HBHelen L. Browne
Helen L. Browne
VTValentina Trapani
Valentina Trapani
TBTracey D. Bradshaw
Tracey D. Bradshaw
MSMalcolm F. G. Stevens
Malcolm F. G. Stevens

8 December 2005 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GFGiovanna Farruggia
Giovanna Farruggia
Stefano IottiStefano Iotti
Stefano Iotti
LPLuca Prodi
Luca Prodi
MMMarco Montalti
Marco Montalti
NZNelsi Zaccheroni
Nelsi Zaccheroni
Federica I. WolfFederica I. Wolf
Federica I. Wolf

30 November 2007 in Clinical Science
Verified
Journal Article
Closed access
PDF file
Federica I. WolfFederica I. Wolf
Federica I. Wolf
VTValentina Trapani
Valentina Trapani
There is an unsettled debate about the role of magnesium as a ‘chronic regulator’ of biological functions, as opposed to the well-known role for calcium as an ‘acute regulator’. New and old findings appear to delineate an increasingly complex and important role for magnesium in many cellular functions. This review summarizes the available evidence for a link between the regulation of intracellular magnesium availability and the control of cell growth, energy metabolism and death, both in healthy and diseased conditions. A comprehensive view is precluded by technical difficulties in tracing magnesium within a multicompartment and dynamic environment like the cell; nevertheless, the last few years has witnessed encouraging progress towards a better characterization of magnesium transport and its storage or mobilization inside the cell. The latest findings pave the road towards a new and deeper appreciation of magnesium homoeostasis and its role in the regulation of essential cell functions.

18 February 2003 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
VTValentina Trapani
Valentina Trapani
VPV Patel
V Patel
CLC-O Leong
C-O Leong
HCH P Ciolino
H P Ciolino
GYG C Yeh
G C Yeh
ALA I Loaiza-Pérez
A I Loaiza-Pérez
The fluorinated benzothiazole analogue 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is a novel agent with potent and selective antitumour properties and, in the form of its L-lysylamide prodrug Phortress (NSC 710305), is a current candidate for early phase clinical studies. Previous findings have indicated that cytochrome P450 1A1 (CYP1A1) may play a role in the antitumour activity of molecules in the benzothiazole series including the nonfluorinated parent compound 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) (Kashiyama et al, 1999; Chua et al, 2000; Loaiza-Pérez et al, 2002). In this study, we assessed and verified that a fully functional aryl hydrocarbon receptor (AhR) signalling pathway is a necessary requisite for the induction of efficient cytotoxicity by 5F 203 in MCF-7 wild-type sensitive cells. Drug exposure caused MCF-7 sensitive cells to arrest in G1 and S phase, and induced DNA adduct formation, in contrast to AhR-deficient AHR100 variant MCF-7 cells. In sensitive MCF-7 cells, induction of CYP1A1 and CYP1B1 transcription (measured by luciferase reporter assay and real-time reverse transcriptase-polymerase chain reaction (RT–PCR)), and 7-ethoxyresorufin-O-deethylase (EROD) activity was demonstrated, following treatment with 5F 203. In contrast, in resistant AHR100 cells, drug treatment did not affect CYP1A1 and CYP1B1 transcription and EROD activity. Furthermore, AHR100 cells failed to produce either protein/DNA complexes on the xenobiotic responsive element (XRE) sequence of CYP1A1 promoter (measured by electrophoretic mobility shift assay) or DNA adducts. The data confirm that activation of the AhR signalling pathway is an important feature of the antitumour activity of 5F 203.

23 October 2021 in European Journal of Nutrition
Verified
Journal Article
Open access
PDF file
VTValentina Trapani
Valentina Trapani
ARAndrea Rosanoff
Andrea Rosanoff
SBShadi Baniasadi
Shadi Baniasadi
MBMario Barbagallo
Mario Barbagallo
SCSara Castiglioni
Sara Castiglioni
JMJeanette Maier
Jeanette Maier
Purpose: In less than one and a half year, the COVID-19 pandemic has nearly brought to a collapse our health care and economic systems. The scientific research community has concentrated all possible efforts to understand the pathogenesis of this complex disease, and several groups have recently emphasized recommendations for nutritional support in COVID-19 patients. In this scoping review, we aim at encouraging a deeper appreciation of magnesium in clinical nutrition, in view of the vital role of magnesium and the numerous links between the pathophysiology of SARS-CoV-2 infection and magnesium-dependent functions. Methods: By searching PubMed and Google Scholar from 1990 to date, we review existing evidence from experimental and clinical studies on the role of magnesium in chronic non-communicable diseases and infectious diseases, and we focus on recent reports of alterations of magnesium homeostasis in COVID-19 patients and their association with disease outcomes. Importantly, we conduct a census on ongoing clinical trials specifically dedicated to disclosing the role of magnesium in COVID-19. Results: Despite many methodological limitations, existing data seem to corroborate an association between deranged magnesium homeostasis and COVID-19, and call for further and better studies to explore the prophylactic or therapeutic potential of magnesium supplementation. Conclusion: We propose to reconsider the relevance of magnesium, frequently overlooked in clinical practice. Therefore, magnesemia should be monitored and, in case of imbalanced magnesium homeostasis, an appropriate nutritional regimen or supplementation might contribute to protect against SARS-CoV-2 infection, reduce severity of COVID-19 symptoms and facilitate the recovery after the acute phase.

1 January 2002 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
ALAndrea I. Loaiza-Pérez
Andrea I. Loaiza-Pérez
VTValentina Trapani
Valentina Trapani
CHCurtis Hose
Curtis Hose
SSSheo S. Singh
Sheo S. Singh
JTJane B. Trepel
Jane B. Trepel
ESEdward A. Sausville
Edward A. Sausville
2-(4-Amino-3-methylphenyl) benzothiazole (NSC 674495; DF 203) demonstrates drug uptake and metabolism by tumor cells sensitive to the antiproliferative activity of the drug [J Med Chem1999;42:4172–4184]. In insensitive cells, little metabolism occurs. Because CYP1A1 can metabolize DF 203, the aryl hydrocarbon receptor (AhR) may mediate drug action. We demonstrate here that DF 203 increases CYP1A1 and CYP1B1 transcription in sensitive MCF-7 cells, accompanied by AhR translocation to the nucleus, increase in xenobiotic-responsive element (XRE)-driven luciferase activity, and induction of protein/DNA complexes on the XRE sequence of the CYP1A1 promoter. MDA-MB-435 and PC3 cells, resistant to DF 203, did not show drug-induced CYP1A1and CYP1B1 gene expression. AhR was observed to be constitutively localized in the nucleus, with no induction of XRE-driven luciferase activity in transiently transfected cells and weak or no induction of protein/DNA complexes on the XRE sequence ofCYP1A1. Taken together, these data elucidate a novel basis for antitumor drug action: induction in sensitive cells of a metabolizing system for the drug itself. These results suggest that clarification of the basis for differential engagement of AhR-related signaling in different tumor cell types may aid in further preclinical development and perhaps early clinical studies.